Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2003

View Archived Issues

Advectus acquires option for nanopharmaceutical for Alzheimer's disease

Cell Therapeutics Scandinavia and Tanabe enter stem cell collaboration

Probactrix controls antibiotic-associated diarrhea in clinical study

Novel 5-HT6 receptor ligands claimed by GSK researchers

Pierre Fabre presents new alpha2-adrenoceptor modulators with potential in AD therapy

BMS scientists prepare and test new anti-HIV agents

Novel p38 inhibitors, their preparation and use covered by GSK patent

Roche identifies new DPP-IV inhibitors

AstraZeneca claims JNK inhibitors for use in AD and other disorders

Humira approved in E.U. for rheumatoid arthritis

Raptiva recommended for approval by advisory committee

Maxalt launched this month in Japan for migraine Rx

Potent antagonist of human glucagon receptor presented at ACS meeting

Selective ERbeta agonist endowed with potent oral antiinflammatory activity

OncoGenex and Isis expand antisense drug development partnership

AVE-5997, a selective, orally active dopamine D3 antagonist, characterized at ACS meeting

Regeneron to advance phase III Axokine program in obesity

Benicar HCT now available in U.S.

Javlor enters two new phase III trials in NSCLC and bladder cancer

BMS designs series of potent and selective Itk inhibitors as potential immunosuppressants

Enrollment completed in phase I breast cancer trial for HER-2 AutoVac Protein vaccine

Merck presents synthesis, SAR for a series of imidazole acetic acid TAFI inhibitors

FDA accepts for filing diquafosol NDA for dry eye

Phase III results for Genasense plus chemotherapy in malignant melanoma

Genzyme expands access to Myozyme

SBIR grant supports smallpox therapeutic development efforts at Aphios

New fluoroquinolone active against multidrug-resistant Gram-positive pathogens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...